Literature DB >> 22898620

Sulforaphane inhibits restenosis by suppressing inflammation and the proliferation of vascular smooth muscle cells.

Jin-Sook Kwon1, Hosouk Joung, Yong Sook Kim, Young-Sun Shim, Youngkeun Ahn, Myung Ho Jeong, Hae Jin Kee.   

Abstract

OBJECTIVE: Sulforaphane, a naturally occurring organosulfur compound in broccoli, has chemopreventive properties in cancer. However, the effects of sulforaphane in vascular diseases have not been examined. We therefore aimed to investigate the effects of sulforaphane on vascular smooth muscle cell (VSMC) proliferation and neointimal formation and the related mechanisms.
METHODS: The expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) was examined in VSMCs. The nuclear translocation of nuclear factor-κB (NF-κB) and GATA6 expression was examined in VSMCs and in a carotid artery injury model by Western blot and immunohistochemistry. We also investigated whether local delivery of sulforaphane affected neointimal formation.
RESULTS: Sulforaphane inhibited the mRNA and protein expression of VCAM-1 induced by tumor necrosis factor (TNF)-α in VSMCs. Treatment of VSMCs with sulforaphane blocked TNF-α-induced IκBα degradation and NF-κB p65 and GATA6 expression. Furthermore, NF-κB p65 and GATA6 expression were reduced in sulforaphane-treated carotid injury sections. Notably, binding of GATA6 to the VCAM-1 promoter was dramatically reduced by sulforaphane. The MTT, BrdU incorporation, and in vitro scratch assays revealed that the proliferation and migration of VSMCs were reduced by sulforaphane. Furthermore, local administration of sulforaphane significantly reduced neointima formation 14 days after vascular injury in rats.
CONCLUSIONS: Our results indicate that sulforaphane inhibits neointima formation via targeting of adhesion molecules through the suppression of NF-κB/GATA6. Furthermore, sulforaphane regulates migration and proliferation in VSMCs. Sulforaphane may be a potential therapeutic agent for preventing restenosis after vascular injury.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22898620     DOI: 10.1016/j.atherosclerosis.2012.07.040

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  18 in total

1.  Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation.

Authors:  Noha M Shawky; Lakshman Segar
Journal:  Pharmacol Res       Date:  2017-02-14       Impact factor: 7.658

Review 2.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

3.  Sulforaphane inhibits IL-1β-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of MMPs, COX-2, and PGE2.

Authors:  Yun Jung Choi; Won-Seok Lee; Eun-Gyeong Lee; Myung-Soon Sung; Wan-Hee Yoo
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

4.  Sulforaphane inhibits TNF-α-induced adhesion molecule expression through the Rho A/ROCK/NF-κB signaling pathway.

Authors:  Chi-Nan Hung; Hui-Pei Huang; Chau-Jong Wang; Kai-Li Liu; Chong-Kuei Lii
Journal:  J Med Food       Date:  2014-09-19       Impact factor: 2.786

5.  Sulforaphane attenuates the development of atherosclerosis and improves endothelial dysfunction in hypercholesterolemic rabbits.

Authors:  George S G Shehatou; Ghada M Suddek
Journal:  Exp Biol Med (Maywood)       Date:  2015-10-20

6.  The 5-hydroxytryptamine transporter is functional in human coronary artery smooth muscle cells proliferation and is regulated by Interleukin-1 beta.

Authors:  Qing-Jie Wang; Dong Wang; Cheng-Chun Tang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice.

Authors:  Noha M Shawky; Prahalathan Pichavaram; George S G Shehatou; Ghada M Suddek; Nariman M Gameil; John Y Jun; Lakshman Segar
Journal:  J Nutr Biochem       Date:  2016-03-10       Impact factor: 6.048

Review 8.  Novel treatment strategies for chronic kidney disease: insights from the animal kingdom.

Authors:  Peter Stenvinkel; Johanna Painer; Makoto Kuro-O; Miguel Lanaspa; Walter Arnold; Thomas Ruf; Paul G Shiels; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2018-01-15       Impact factor: 28.314

9.  Sulforaphane reduces vascular inflammation in mice and prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.

Authors:  Palanisamy Nallasamy; Hongwei Si; Pon Velayutham Anandh Babu; Dengke Pan; Yu Fu; Elizabeth A S Brooke; Halley Shah; Wei Zhen; Hong Zhu; Dongmin Liu; Yunbo Li; Zhenquan Jia
Journal:  J Nutr Biochem       Date:  2014-04-04       Impact factor: 6.048

Review 10.  Targeting oxidative stress in disease: promise and limitations of antioxidant therapy.

Authors:  Henry Jay Forman; Hongqiao Zhang
Journal:  Nat Rev Drug Discov       Date:  2021-06-30       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.